ERBB2 and breast carcinoma: To test whether the expression level of TMEM88 varied in breast cancers with distinct ER, PR, and Her2 expression patterns, the relationship between TMEM88 expression and clinicopathological factors was examined in triple-negative and triple-positive breast cancer tissues, respectively.